Heikkilä H, Stubb S, Reitamo S
Department of Dermatology, Helsinki University Central Hospital, Finland.
Br J Dermatol. 1996 Apr;134(4):678-80. doi: 10.1111/j.1365-2133.1996.tb06969.x.
Over a 3 1/2 year period, from 1991 to 1994, we detected contact allergy to tioconazole in 72 patients by epicutaneous testing. During this period, tioconazole was included in the standard series of epicutaneous tests. Except for the first 6 months, the incidence of positive patch test reactions to tioconazole was over 1% of patients tested for contact allergy. As well as those tested with the standard series, 18 additional patients with tioconazole allergy were detected by direct testing with an imidazole patch test series. Of the various imidazole derivatives, tioconazole was the most important contact allergen. About half of patients with contact hypersensitivity to tioconazole, had additional contact allergies detected by the standard series. Men and women were equally affected. The present study suggests that tioconazole is an important contact allergen, which should be included into the patch test series in countries where it is used as a topical antifungal agent.
在1991年至1994年的3年半时间里，我们通过皮肤试验在72例患者中检测到对酮康唑的接触性过敏。在此期间，酮康唑被纳入皮肤试验的标准系列。除了最初的6个月，对酮康唑进行斑贴试验反应阳性的发生率超过接受接触性过敏检测患者的1%。除了用标准系列进行检测的患者外，通过用咪唑斑贴试验系列直接检测又发现了18例对酮康唑过敏的患者。在各种咪唑衍生物中，酮康唑是最重要的接触性变应原。对酮康唑接触过敏的患者中约有一半通过标准系列检测出有其他接触性过敏。男性和女性受影响程度相同。本研究表明，酮康唑是一种重要的接触性变应原，在将其用作外用抗真菌剂的国家，应将其纳入斑贴试验系列。
